Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer
“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Karim Fizazi, MD, PhD, about results from a game-changing study that was presented at the 2022 ASCO Genitourinary Cancers Symposium. The phase 3 ARASENS trial showed that a darolutamide-based triplet regimen improved overall survival in patients with metastatic hormone-sensitive prostate cancer. Fizazi is a medical oncologist and head of the department of cancer medicine at the Institute of Gustave Roussy, and professor of oncology at the University of Paris Sud in Villejuif, France.
